Fortrea Holdings (FTRE) Non-Current Assets (2022 - 2026)
Fortrea Holdings (FTRE) posted Non-Current Assets of $1.8 billion for Q1 2026, down 0.91% on a QoQ basis from $1.8 billion in Q4 2025, and down 16.22% year-over-year from $2.2 billion in Q1 2025.
Fortrea Holdings (FTRE) Non-Current Assets (2022 - 2026) Analysis & Trends
Fortrea Holdings' Non-Current Assets history runs 5 years deep, the most recent figure standing at $1.8 billion for Q1 2026.
- Quarterly Non-Current Assets fell 16.22% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 billion (down 28.15% YoY) and the FY2025 annual result came in at $1.8 billion, down 30.88% from the prior year.
- Non-Current Assets was $1.8 billion for Q1 2026 at Fortrea Holdings, down from $1.8 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $3.1 billion in Q2 2023 and bottomed at $1.8 billion in Q1 2026.
- A 5-year average of $2.5 billion and a median of $2.7 billion in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets advanced 1.34% — and 2025, when it plunged 33.12%.
- Fortrea Holdings' Non-Current Assets stood at $3.0 billion in 2022, then rose by 1.34% to $3.1 billion in 2023, then declined by 14.63% to $2.6 billion in 2024, then tumbled by 30.88% to $1.8 billion in 2025, then dropped by 0.91% to $1.8 billion in 2026.
- Business Quant data shows FTRE's Non-Current Assets at $1.8 billion in Q1 2026, $1.8 billion in Q4 2025, and $1.8 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | 1.80 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.80 Bn |
| Dec 31, 2025 | 1.82 Bn |
| Sep 30, 2025 | 1.82 Bn |
| Jun 30, 2025 | 1.88 Bn |
| Mar 31, 2025 | 2.15 Bn |
| Dec 31, 2024 | 2.63 Bn |
| Sep 30, 2024 | 2.73 Bn |
| Jun 30, 2024 | 2.68 Bn |
| Mar 31, 2024 | 3.04 Bn |
| Dec 31, 2023 | 3.08 Bn |
| Sep 30, 2023 | 3.06 Bn |
| Jun 30, 2023 | 3.12 Bn |
| Dec 31, 2022 | 3.04 Bn |